Developing a new peptide drug to treat Alzheimer's disease
Multi-target Peptide Drug for Alzheimer's Disease
This study is testing a new drug called ALZ100, which is designed to help people with Alzheimer's by tackling several problems in the brain at once, and it will be tested in lab models to see how well it works.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Alzarrok Bio LLC NIH-funded |
| Lab location | 1 site (Midwest City, United States) |
| Project ID | NIH-10921064 on NIH RePORTER |
What this research studies
This research focuses on creating a peptide drug called ALZ100, derived from a human defense protein, to target multiple pathways involved in Alzheimer's disease. Unlike existing treatments that typically address a single aspect of the disease, ALZ100 aims to inhibit several key mediators that contribute to neurodegeneration and inflammation in the brain. The study will assess the drug's effectiveness in laboratory models to demonstrate its ability to engage and inhibit these targets, potentially leading to improved outcomes for patients with Alzheimer's.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease who are seeking new treatment options.
Not a fit: Patients with other forms of dementia or those who do not have Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for Alzheimer's patients by addressing multiple disease mechanisms simultaneously.
How similar studies have performed: While multitarget approaches in Alzheimer's treatment are being explored, this specific peptide drug represents a novel strategy that has not been widely tested in clinical settings.
Where this research is happening
Midwest City, United States
- Alzarrok Bio LLC — Midwest City, United States (Active)
Researchers
- Principal investigator: Kasus-Jacobi, Anne — Alzarrok Bio LLC
- Study coordinator: Kasus-Jacobi, Anne
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.